Kymera Therapeutics (KYMR) Leases (2019 - 2025)
Historic Leases for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $42.9 million.
- Kymera Therapeutics' Leases fell 1064.81% to $42.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year decrease of 1064.81%. This contributed to the annual value of $47.4 million for FY2024, which is 1045.99% down from last year.
- Kymera Therapeutics' Leases amounted to $42.9 million in Q3 2025, which was down 1064.81% from $46.0 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Leases registered a high of $56.6 million during Q1 2023, and its lowest value of $8.9 million during Q4 2022.
- In the last 5 years, Kymera Therapeutics' Leases had a median value of $46.0 million in 2025 and averaged $32.9 million.
- As far as peak fluctuations go, Kymera Therapeutics' Leases surged by 50818.74% in 2023, and later tumbled by 1285.24% in 2024.
- Over the past 5 years, Kymera Therapeutics' Leases (Quarter) stood at $9.4 million in 2021, then fell by 5.48% to $8.9 million in 2022, then skyrocketed by 494.29% to $52.9 million in 2023, then dropped by 10.46% to $47.4 million in 2024, then fell by 9.41% to $42.9 million in 2025.
- Its Leases was $42.9 million in Q3 2025, compared to $46.0 million in Q2 2025 and $46.7 million in Q1 2025.